OSE & MAbSilico inject AI into therapeutic antibody drug development

OSE Immunotherapeutics has teamed up with French start-up MAbSilico to use artificial intelligence-based solutions for therapeutic antibody drug development.

OSE Immunotherapeutics, a French biotech focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases, said it plans to incorporate innovative problem-solving solutions like AI for the development of new monoclonal antibodies.

MAbSilico solutions have already been tested and validated by OSE Immunotherapeutics and will be used for six antibody programs, including novel bispecific antibodies.

AI and numerical simulation can guide therapeutic antibody discovery, help reduce the risk of failure and accelerate the pre-clinical development process of these drug candidates before clinical tests.

“Due to the devastating nature of these [immuno-oncology and autoimmune] diseases, our development strategies need to be accelerated and artificial intelligence solutions for drug discovery offered by MAbSilico can be a great asset to achieve this goal,” said Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics.

While all MAbSilico’s commercialised solutions are included in this three-year agreement, OSE Immunotherapeutics also gains early access to MAbSilico’s SaaS (Software as a Service) and technologies in development including those for the conception of therapeutic antibodies optimised for bioproduction.

OSE provides internal data to MAbSilico in order to feed their algorithms in development and deliver new technology faster.

Vincent Puard, CEO of MAbSilico, said: “This partnership demonstrates the need to fasten new AI-based solutions for antibody drug discovery. We believe that with the trust and collaboration of OSE, we will accelerate the release of our software and new technologies.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...

New class of precision medicine strips cancer of its DNA defences

A new precision medicine targeting cancer’s ability to repair its DNA has shown promising results in the first clinical trial of the drug class. The...

Tonix & Southern Research expand COVID-19 vaccine collaboration to include T cell study

New York biopharma, Tonix Pharmaceuticals, has expanded its strategic collaboration with Southern Research to include a study of T cell immune responses to SARS-CoV-2...

Related news

Avalon GloboCare & BOKU to advance intranasal & oral COVID-19 vaccine candidate

Avalon GloboCare, a New Jersey-based clinical-stage global developer of cell-based technologies and therapeutics, has partnered with the University of Natural Resources and Life Sciences...

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...